Literature DB >> 30741738

Individualized Dynamics in the Gut Microbiota Precede Crohn's Disease Flares.

Tzipi Braun1, Ayelet Di Segni1, Marina BenShoshan1,2, Sandra Neuman3, Nina Levhar3, Michael Bubis3, Orit Picard3, Katya Sosnovski1,2, Gilat Efroni1, Sarit Farage Barhom1, Efrat Glick Saar1, Avishay Lahad2,4, Batia Weiss2,4, Doron Yablecovitch2,3, Adi Lahat2,3, Rami Eliakim2,3, Uri Kopylov2,3, Shomron Ben-Horin2,3, Yael Haberman2,4,5.   

Abstract

OBJECTIVES: Crohn's disease (CD) is a chronic relapsing-remitting gut inflammatory disorder with a heterogeneous unpredictable course. Dysbiosis occurs in CD; however, whether microbial dynamics in quiescent CD are instrumental in increasing the risk of a subsequent flare remains undefined.
METHODS: We analyzed the long-term dynamics of microbial composition in a prospective observational cohort of patients with quiescent CD (45 cases, 217 samples) over 2 years or until clinical flare occurred, aiming to identify whether changes in the microbiome precede and predict clinical relapse. Machine learning was used to prioritize microbial and clinical factors that discriminate between relapsers and nonrelapsers in the quiescent phase.
RESULTS: Patients with CD in clinical, biomarker, and mucosal remission showed significantly reduced microbial richness and increased dysbiosis index compared with healthy controls. Of the 45 patients with quiescent CD, 12 (27%) flared during follow-up. Samples in quiescent patients preceding flare showed significantly reduced abundance of Christensenellaceae and S24.7, and increased abundance of Gemellaceae compared with those in remission throughout. A composite flare index was associated with a subsequent flare. Notably, higher individualized microbial instability in the quiescent phase was associated with a higher risk of a subsequent flare (hazard ratio 11.32, 95% confidence interval 3-42, P = 0.0035) using two preflare samples. Importantly, machine learning prioritized the flare index and the intrapersonal instability over clinical factors to best discriminate between relapsers and nonrelapsers. DISCUSSION: Individualized microbial variations in quiescent CD significantly increase the risk of future exacerbation and may provide a model to guide personalized preemptive therapy intensification.

Entities:  

Mesh:

Year:  2019        PMID: 30741738     DOI: 10.14309/ajg.0000000000000136

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  19 in total

1.  Fecal microbiota signatures of insulin resistance, inflammation, and metabolic syndrome in youth with obesity: a pilot study.

Authors:  Federica Del Chierico; Melania Manco; Simone Gardini; Valerio Guarrasi; Alessandra Russo; Marzia Bianchi; Valentina Tortosa; Andrea Quagliariello; Blegina Shashaj; Danilo Fintini; Lorenza Putignani
Journal:  Acta Diabetol       Date:  2021-03-22       Impact factor: 4.280

Review 2.  Contribution of the Intestinal Microbiome and Gut Barrier to Hepatic Disorders.

Authors:  Daniel M Chopyk; Arash Grakoui
Journal:  Gastroenterology       Date:  2020-06-20       Impact factor: 22.682

3.  Composite outcomes in observational studies of Crohn's disease: a systematic review and meta-analysis.

Authors:  Fernando Magro; Catarina Sottomayor; Catarina Alves; Mafalda Santiago; Paula Ministro; Paula Lago; Luís Correia; Raquel Gonçalves; Diana Carvalho; Francisco Portela; Cláudia Camila Dias; Axel Dignass; Silvio Danese; Laurent Peyrin-Biroulet; Maria Manuela Estevinho; Paula Leão Moreira
Journal:  Therap Adv Gastroenterol       Date:  2022-05-13       Impact factor: 4.802

Review 4.  Systematic Review: The Gut Microbiome and Its Potential Clinical Application in Inflammatory Bowel Disease.

Authors:  Laila Aldars-García; María Chaparro; Javier P Gisbert
Journal:  Microorganisms       Date:  2021-04-30

5.  Multi-omic Analysis of the Interaction between Clostridioides difficile Infection and Pediatric Inflammatory Bowel Disease.

Authors:  Frederic D Bushman; Maire Conrad; Yue Ren; Chunyu Zhao; Christopher Gu; Christopher Petucci; Min-Soo Kim; Arwa Abbas; Kevin J Downes; Nina Devas; Lisa M Mattei; Jessica Breton; Judith Kelsen; Sarah Marakos; Alissa Galgano; Kelly Kachelries; Jessi Erlichman; Jessica L Hart; Michael Moraskie; Dorothy Kim; Huanjia Zhang; Casey E Hofstaedter; Gary D Wu; James D Lewis; Joseph P Zackular; Hongzhe Li; Kyle Bittinger; Robert Baldassano
Journal:  Cell Host Microbe       Date:  2020-08-20       Impact factor: 31.316

6.  Defining the Celiac Disease Transcriptome using Clinical Pathology Specimens Reveals Biologic Pathways and Supports Diagnosis.

Authors:  Nurit Loberman-Nachum; Katya Sosnovski; Ayelet Di Segni; Gilat Efroni; Tzipi Braun; Marina BenShoshan; Lait Anafi; Camila Avivi; Iris Barshack; Dror S Shouval; Lee A Denson; Amnon Amir; Ron Unger; Batia Weiss; Yael Haberman
Journal:  Sci Rep       Date:  2019-11-07       Impact factor: 4.379

7.  Yearly changes in the composition of gut microbiota in the elderly, and the effect of lactobacilli intake on these changes.

Authors:  Ryuta Amamoto; Kazuhito Shimamoto; Sungjin Park; Hoshitaka Matsumoto; Kensuke Shimizu; Miyuki Katto; Hirokazu Tsuji; Satoshi Matsubara; Roy J Shephard; Yukitoshi Aoyagi
Journal:  Sci Rep       Date:  2021-06-17       Impact factor: 4.379

Review 8.  Microbiota-host interactions shape ageing dynamics.

Authors:  Miriam Popkes; Dario Riccardo Valenzano
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2020-08-10       Impact factor: 6.237

Review 9.  The Interplay between Immune System and Microbiota in Inflammatory Bowel Disease: A Narrative Review.

Authors:  Laila Aldars-García; Alicia C Marin; María Chaparro; Javier P Gisbert
Journal:  Int J Mol Sci       Date:  2021-03-17       Impact factor: 5.923

10.  The Keystone commensal bacterium Christensenella minuta DSM 22607 displays anti-inflammatory properties both in vitro and in vivo.

Authors:  Camille Kropp; Katy Le Corf; Karima Relizani; Kevin Tambosco; Ccori Martinez; Florian Chain; Georges Rawadi; Philippe Langella; Sandrine P Claus; Rebeca Martin
Journal:  Sci Rep       Date:  2021-06-01       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.